Press releases

30 Jan 2026

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)

13 Jan 2026

Innovation and Execution Power UCB’s Success

8 Dec 2025

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

5 Dec 2025

UCB Upgrades 2025 Financial Guidance Based on Strong Performance

4 Dec 2025

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

6 Nov 2025

UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation

Press releases

Press releases

Search Press releases

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)

Innovation and Execution Power UCB’s Success

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

UCB Upgrades 2025 Financial Guidance Based on Strong Performance

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)

Innovation and Execution Power UCB’s Success

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

UCB Upgrades 2025 Financial Guidance Based on Strong Performance

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

UCB Announces Strategic Executive Leadership Rotation to Drive Future Growth and Innovation

Choose a Country